Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

NCT06208462 | Recruiting Phase 2 DMC

• 1 other identifier: NEO-ERA-01
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 3

Brief Summary

Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.

Conditions

Intrahepatic Cholangiocarcinoma

Outcome Measures

Primary Outcomes (1)

• Propotion of treatment completion

  Propotion of treatment completion (including neo-adjuvant therapy and surgery)

  one year

Secondary Outcomes (10)

• Assess safety and tolerability

  one year

• OS

  one year

• pCR

  one year

• R0 resection rate

  one year

• Major pathological response (MPR)

  Until the surgery is over

Study Arms (1)

Combined treatment group

EXPERIMENTAL

1. Preoperative treatment 3 weeks is a course of treatment HAIC (GEMOX) chemotherapy 1. It is performed within one week after the identification of ICC 2. Day 1 HAIC (GEMOX) Oxaliplatin 85mg/m2 + Gemcitabine 800mg/m2 Adebrelimab: Day 3 Adebrelimab 1200mg i.v. Lenvatinib 2# qd 2. Evaluation every 2 courses, up to 4 courses. 3. Liver resection: It is performed within 1 month after preoperative treatment. 4. Postoperative treatment: Day 1-14 Capecitabine 1200mg B.I.D.

Drug: Adebrelimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin

Interventions

Adebrelimab DRUG

1200mg，i.v. , q3w

Also known as: SHR-1316

Combined treatment group

Lenvatinib DRUG

8mg,qd

Also known as: 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide

Combined treatment group

Gemcitabine DRUG

800 mg/m2，q3w

Also known as: Difluorodeoxycytidine Hydrochloride

Combined treatment group

Oxaliplatin DRUG

85 mg/m2，q3w

Also known as: Diaminocyclohexane Oxalatoplatinum

Combined treatment group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient must sign the informed consent;
• Age 18-75 years old, male and female;
• ECOG Physical status Score (PS score) 0 or 1;
• Patients with ICC who have been pathologically diagnosed (histopathological and/or cytological examination) or clinically diagnosed as having high-risk factors;
• Risk factors are defined as follows:
• Stage ≥Ib, single lesion \> 5cm, multiple tumor lesions in the same lobe, technically resectable;Vascular invasion, regional lymph node metastasis, technically resectable
• Patients with untreated and resectable locally advanced ICC who have been assessed by the surgeon as surgically resectable;
• The functional indicators of vital organs meet the following requirements
• ① Neutrophils ≥1.5\*109/L; Platelet ≥80\*109/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl;② Thyroid stimulating hormone (TSH) ≤ 1 times the upper limit of normal, T3, T4 in the normal range;③ Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤ 2 times the upper limit of normal value;④ Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min;
• The subject has at least one measurable lesion (according to RECIST1.1);
• Fertile women: must agree to abstain from sex (abstain from heterosexual intercourse) or use a reliable, effective method of contraception for at least 120 days from the signing of the informed consent until the final administration of the study drug. Serum HCG test must be negative within 72 hours before randomization. And must be non-lactating.A woman is considered fertile if she has menstruated, has not yet reached postmenopausal status (no continuous periods for ≥12 months, no cause other than menopause has been found), and has not undergone sterilization (such as hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
• For male subjects whose partner is a fertile woman, they must agree to abstain from sex or use a reliable, effective method of contraception for at least 120 days from the signing of the informed consent until the final administration of the study drug. Male subjects also had to agree not to donate sperm during the same time period. Male subjects with a pregnant partner are required to use condoms and do not need to use other methods of contraception.

You may not qualify if:

• Pathological diagnosis of hepatocellular carcinoma, mixed hepatocellular carcinoma and other non-cholangiocarcinoma malignant tumor components;
• Prior systemic therapy and tumor-related surgical treatment (biliary drainage allowed);Patients who relapse after surgery, have received PD1 antibody, PDL1 antibody or CTLA4 antibody, Lenvatinib, chemotherapy in the past; participated in other clinical trials 30 days before screening
• Previous or co-existing malignancies other than adequately treated non-melanin skin cancer, cervical carcinoma in situ and thyroid papillary carcinoma;
• Active pulmonary tuberculosis infection. Patients with active pulmonary tuberculosis infection within 1 year prior to enrollment; Had a history of active tuberculosis infection more than 1 year before enrollment, had not received formal anti-tuberculosis therapy or had active tuberculosis;
• Have an active, known, or suspected autoimmune disease. Subjects with hypothyroidism requiring hormone replacement therapy and skin conditions that do not require systemic therapy are eligible;
• Long-term acceptance of systemic sex hormones (doses equivalent to \> 10mg prednisone per day) or any other form of immunosuppressive therapy. Participants using inhaled or topical corticosteroids may be enrolled;
• Severe cardiopulmonary and renal dysfunction;
• Have hypertension that is not well controlled by antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg);
• Abnormal coagulation function (PT\> 14s), have a tendency to bleed or are receiving thrombolytic or anticoagulant therapy;
• HBV DNA\> 2000IU/ml, HCV RNA\> 1000 IU/ml;
• Had clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;
• Active infections that require systemic treatment;
• Human immunodeficiency virus (HIV, HIV1/2 antibodies) positive;
• Have a history of psychotropic substance abuse, alcohol abuse or drug use;
• Have a history of drug allergy;

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead
• Jiangsu Hengrui Pharmaceutical Co., Ltd.: collaborator

Study Sites (3)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

RECRUITING

West China Hospital

Chengdu, Sichuan, 610000, China

RECRUITING

Ningbo Medical Center Lihuili Hospital

Ningbo, Zhejiang, 315000, China

RECRUITING

MeSH Terms

Conditions

Cholangiocarcinoma

Interventions

lenvatinib; Gemcitabine; Oxaliplatin

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Coordination Complexes; Organic Chemicals

Study Officials

• Feng Cheng, MD

  The First Affiliated Hospital with Nanjing Medical University

  STUDY DIRECTOR

Central Study Contacts

Feng Cheng, MD

CONTACT

13305170695; docchengfeng@njmu.edu.cn

Jianhua Rao, MD

CONTACT

18262637266; raojh@njmu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2024
• First Posted: January 17, 2024
• Study Start: January 19, 2024
• Primary Completion: January 1, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: March 3, 2025

Record last verified: 2025-01

Locations

CN (3)